Allergan has reported its fourth quarter and full year 2016 continuing operations performance.
Fourth Quarter and Full-Year 2016 Continuing Operations
View Table Fullscreen
(unaudited; $ in millions, except per share amounts)
Q4 '16
Q4 '15
Q3 '16
Q4 '16 v Q4 '15
Q4 '16 v Q3 '16
Twelve Months Ended December 31, 2016
Twelve Months Ended December 31, 2015
2016 v 2015
Total net revenues**
$ 3,864.3
$ 3,606.9
$ 3,622.2
7.1%
6.7%
$ 14,570.6
$ 12,688.1
14.8%
Operating (Loss)
$ (900.0)
$ (569.5)
$ (266.4)
58.0%
237.8%
$ (1,825.5)
$ (3,131.0)
(41.7)%
Diluted EPS - Continuing Operations
$ (0.31)
$ (2.18)
$ (1.15)
(85.8)%
(73.0)%
$ (3.17)
$ (8.64)
(63.3)%
SG&A Expense
$ 1,276.8
$ 1,276.3
$ 1,157.2
0.0%
10.3%
$ 4,740.3
$ 4,481.5
5.8%
R&D Expense
$ 913.3
$ 430.6
$ 622.8
112.1%
46.6%
$ 2,575.7
$ 2,358.5
9.2%
Continuing Operations Tax Rate
96.4%
12.7%
29.5%
83.7%
66.9%
67.0%
35.3%
31.7%
Non-GAAP Adjusted Operating Income
$ 1,868.7
$ 1,867.3
$ 1,784.4
0.1%
4.7%
$ 7,245.3
$ 6,781.4
6.8%
Non-GAAP Performance Net Income Per Share *
$ 3.90
$ 3.36
$ 3.32
16.1%
17.5%
$ 13.51
$ 13.20
2.3%
Non-GAAP Adjusted EBITDA
$ 1,975.7
$ 1,951.8
$ 1,902.2
1.2%
3.9%
$ 7,628.7
$ 7,086.7
7.6%
Non-GAAP SG&A Expense
$ 1,067.0
$ 997.0
$ 1,006.9
7.0%
6.0%
$ 4,081.7
$ 3,324.0
22.8%
Non-GAAP R&D Expense
$ 425.9
$ 338.1
$ 386.4
26.0%
10.2%
$ 1,433.8
$ 1,116.8
28.4%
Non-GAAP Continuing Operations Tax Rate
10.4%
7.6%
8.2%
2.8%
2.2%
8.9%
7.7%
1.2%
&nb...
(All Rights Reserved)